Abstract 5147
Background
Patient rights has been developed from human rights. Human rights emerged from the Universal Declaration of Human Rights. The Declaration is a milestone document in the history of human rights (1). Today the patient’s rights have become an important issue on the political agenda. Individual’s awareness of their own rights in the health area is constantly increasing. Patient’s rights are becoming primary concern in improving quality of health care (2). Today the patient becomes the consumer (3). The most important role that nurses have is delivering quality care for the patients and also act as patient advocates. Nurses must understand the importance of patient rights. The main aim of the survey is to analyze, investigate, compare and present, the legal framework of the patient’s rights legislation in the European Union.
Methods
A literature search and review related to the patient right was conducted using PubMed, Cinahl, Medline and Google Scholar. With descriptive method we set up a theoretical framework of the patient’s rights legislation. We also use comporative method to discover the similarities and differences between legal systems and their components.
Results
Patient’s rights are in thirteen European Member States regulated by specific law - Law on patient’s rights.
Conclusions
EU Member States do not have a common legislation for patient’s rights. Patient’s rights vary from country to country. Some countries have a single law or act, others use multiple pieces of legislation. Nurses are an important voice of the patient. References: 1. Universal Declaration of Human Rights. Avalible at: Https://www.un.org/en/universal-declaration-human-rights/ (10. 4. 2019). 2. Opinion of the European Economic and Social Committee on Patients’ rights. Official Journal EU, C10/67. Avalible at: Https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2008:010:0067:0071:EN:PDF (10. 4. 2019). 3. OECD - Patients, Patient Organisations and the Production of Medical Science and Technology. Avalible at: Http://www.oecd.org/education/innovation-education/32126031.pdf (10. 4. 2019). 4. Kozuh M., 2016. Legal Arrangements for the Protection of Patients’ Rights: A Comparative Overview of the Regulation in the EU (Master Thesis). University of Primorska Slovenia.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Maja Kozuh.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1242 - Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data.
Presenter: Roger Cohen
Session: Poster Display session 3
Resources:
Abstract
4703 - Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck
Presenter: Katsumi Hirose
Session: Poster Display session 3
Resources:
Abstract
3638 - Phase 3 KEYNOTE-048 Study of First-Line (1L) Pembrolizumab (P) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Asia vs Non-Asia Subgroup (subgrp) Analysis
Presenter: Makoto Tahara
Session: Poster Display session 3
Resources:
Abstract
2954 - Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
3629 - First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
Presenter: Caroline Even
Session: Poster Display session 3
Resources:
Abstract
767 - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
Presenter: Theodoros Rampias
Session: Poster Display session 3
Resources:
Abstract
4985 - A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with Nivolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck.
Presenter: Paolo Bossi
Session: Poster Display session 3
Resources:
Abstract
1564 - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy
Presenter: Jingjing Miao
Session: Poster Display session 3
Resources:
Abstract
3356 - To compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy
Presenter: Yuan-Yuan Chen
Session: Poster Display session 3
Resources:
Abstract
1984 - Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)
Presenter: Gizem Kaval
Session: Poster Display session 3
Resources:
Abstract